In a new study, the OMRF compound OKN-007 is being combined with the current standard-of-care medication for glioblastoma.
Oblato acquires all rights to glioblastoma drug from OMRF
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
OMRF enters into a license agreement with Shanghai RAAS Blood Products
OMRF has entered a license agreement with Shanghai RAAS Blood Products for development of novel hemophilia treatment.
Pet Rx: Can human health research benefit our four-legged friends?
Health advancements made at OMRF could translate to better health for your pets.
Eisai, OMRF enter autoimmune disease research collaboration
The project is focused on lupus, which affects up to 1.5 million Americans.
Biotech company acquires OMRF brain cancer drug
Agreement will expand clinical trials of glioblastoma drug